Spontaneous and carcinogen−induced tumorigenesis in p53−deficient mice

Nature Genetics

Volumn 5, Issue 3, 1993, Pages 225-229

  Harvey, Michele ^a   McArthur, Mark J ^a   Montgomery, Charles A ^a   Butel, Janet S ^a   Bradley, Allan ^a   Donehower, Lawrence A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE TARGETING; HETEROZYGOTE; HOMOZYGOTE; LYMPHOMA; MOUSE; NONHUMAN; OSTEOSARCOMA; SOFT TISSUE SARCOMA;

ANIMAL; DIMETHYLNITROSAMINE; GENES, P53; HETEROZYGOTE; HOMOZYGOTE; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

ANIMALIA;

EID: 0027521657     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng1193-225     Document Type: Article

References (34)

1. Levine, A. J., Momand, J. & Finlay, C. A. The p53 tumour suppressor gene. Nature 351, 453-456 (1991).
2. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C. C. p53 mutations in human cancers. Science 253, 49-53 (1991).
3. Caron de Fromentel, C. & Soussi, T. TP53 tumor suppressor gene: A model for investigating human mutagenesis. Genes, Chrom. Cancer 4, 1-15 (1992).
4. Chang, F., Syrjanen, S., Kurvinen, K. & Syrjanen, K. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am. j. Gastroenterol. 88, 174-186 (1993).
5. Nigro, J. M. et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342, 705-708 (1989).
6. Masuda, H., Miller, C., Koeffler, H. P., Battifora, H., Cline, M. J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. natn. Acad. Sci. U. S. A. 84, 7716-7719 (1987).
7. Saylors, R. L. et al. Infrequent p53 gene mutations in medulloblastomas. Cancer Res. 51, 4721-4723 (1991).
8. Preudhomme, C. et al. Rare occurrence of p53 gene mutations in multiple myeloma. Br. J. Haematol. 81, 440 (1992).
9. Tsushita, K., Hotta, T., Ichikawa, A. & Saito, H. Mutation of p53 gene does not play a critical role in myelodysplastic syndrome and its transformation to acute leukaemia. Br. J. Haematol. 81, 456 (1992).
10. Moll, U., Riou, G. & Levine, A. J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. natn. Acad. Sci. U. S. A. 89, 7262-7266 (1992).
11. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238 (1990).
12. Srivastava, S., Zou, Z., Pirollo, K., Blattner, W. & Chang, E. Germ-line transmission of a mutated p53 gene in a cancerprone family with Li-Fraumeni syndrome. Nature 348, 747-749 (1990).
13. Toguchida, J. et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. New Engl. J. Med. 326, 1301-1308 (1992).
14. Malkin, D. et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. New Engl. J. Med. 326, 1309-1315 (1992).
15. Ben-David, Y. & Bernstein, A. Friend virus-induced erythroleukemia and the multistage nature of cancer. Cell 66, 831-834 (1991).
16. Lavigueur, A. et al. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Molec. cell. Biol. 9, 3982-3991 (1989).
17. Milner, J. & Medcalf, E. A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65, 765-774 (1991).
18. Kern, S. et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830 (1992).
19. Farmer, G. et al. Wild-type p53 activates transcription in vitro. Nature 358, 83-86 (1992).
20. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
21. Clapp, N. K., Craig, A. W. & Toya, R. E. Sr. Pulmonary and hepatic oncogenesis during treatment of male RF mice with dimethylnitrosamine. J. natn Cancer Inst. 41, 1213-1221 (1968).
22. Livingstone, L. et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70, 923-935 (1992).
23. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C. & Wahl, G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70, 937-948 (1992).
24. Kastan, M. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597 (1992).
25. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. & Jacks, T. p53 is required for radiation-induced apoptosis. Nature 362, 847-849 (1993).
26. Clarke, A. R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852 (1993).
27. Triche, T. J. Unique features of childhood cancer. In Cancer Medicine, 3rd edn, (eds Holland, J. F. et al.) 2144-2152 (Lea & Febiger, Malvern, Philadelphia, 1993).
28. Miller, R. W. & Dalager, B. U. S. childhood deaths by cell type. J. Pediat. 85, 664 (1974).
29. Parkin, D. M. et al. Results from Contributing Centers-List of Tables. InInternational Incidence of Childhood Cancer, No. 87, 101-107 (Oxford University Press, 1988).
30. Hansen, M. F. & Cavenee, W. K. Genetics of cancer predisposition. Cancer Res. 47, 5518-5527 (1987).
31. Fournier, P. Biotransformation of dimethylnitrosamine. J. Toxicol. Clin. Exp. 10, 283-296 (1990).
32. Pritchard, D. J. & Butler, W. H. Apoptosis-The mechanism of cell death in dimethylnitrosamine-induced hepatotoxicity. J. Pathol. 158, 253-260 (1989).
33. Kemp, C., Donehower, L. A., Bradley, A. & Balmain, A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74, 813-822 (1993).
34. Burns, P. A. et al. Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice. Oncogene 6, 2363-2369 (1991).